Effect of sodium houttuyfonate on myocardial hypertrophy in mice and rats

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 5, 2009, Pages 677-683

  Jian, Ping Gao ^a   Chang, Xun Chen ^a   Ying, Wang ^a   Jian, Lü ^a   Wei, Liang Gu ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Angiotensin II; cAMP; Endothelin 1; Hydroxyproline; Myocardial hypertrophy; Sodium houttuyfonate

Indexed keywords

ANGIOTENSIN II; CAPTOPRIL; CARDIAC AGENT; CYCLIC AMP; ENDOTHELIN 1; HYDROXYPROLINE; ISOPRENALINE; LEVOTHYROXINE; SODIUM HOUTTUYFONATE; UNCLASSIFIED DRUG; ALKANE; SULFITE; THYROXINE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; HEART LEFT VENTRICLE WEIGHT INDEX; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HEART WEIGHT INDEX; MALE; MOUSE; NONHUMAN; RADIOIMMUNOASSAY; RAT; TREATMENT RESPONSE; ANIMAL; BLOOD; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; HEART MUSCLE; METABOLISM; ORGAN SIZE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ALKANES; ANGIOTENSIN II; ANIMALS; CAPTOPRIL; CARDIOMEGALY; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; HYDROXYPROLINE; ISOPROTERENOL; MALE; MICE; MYOCARDIUM; MYOCYTES, CARDIAC; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SULFITES; THYROXINE;

EID: 68949086670     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.05.0018     Document Type: Article

References (37)

1. Fuster V et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-531.
2. Schillaci G et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-586.
3. Yang J et al. Synthesis of sodium houttuyfonate. West China J Pharm Sci 2005; 20: 30-31.
4. Cheng X et al. Initial study on sodium houttuyfonate (injectable powder): antimicrobial activity in vitro. Lishizhen Med Materia Med Res 2005; 16: 465-466.
5. Zhao Z et al. Antimicrobial activity of berberine hydrochloride, sodium houttuyfonate and allicin in vitro. Chin J Clin Pharmacol 2005; 21: 119-121.
6. Wang D et al. Studies on adjuvanticity of sodium houttuyfonate and its mechanism. Int Immunopharmacol 2002; 2: 1411-1418.
7. Wang JY, Fan SK. Clinical application of herba houttuyniae injection. Beijing J Tradit Chin Med 1999; 4: 61-62.
8. Gan B. Observation on the effect of herba houttuyniae injection treatment in cases with pulmonary heart disease (in acute period) through atomizing inhalation. J Chin Physician 2004; 32: 45-46.
9. Guan LP, Xia SX. Observation on the effect of herba houttuyniae injection treatment in 92 cases with pulmonary heart disease. J Clin Pulmonary Med 2004; 9: 369
10. Wang HH et al. Experimental study on herba houttuyniae injection against myocardial injury induced by endotoxin. Chin J Pathophysiol 2004; 20: 387-390.
11. Iaccarino G et al. Beta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by beta- but not alpha1-adrenergic stimulation. Hypertension 1999; 33: 396-401.
12. Morisco C et al. Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. J Mol Cell Cardiol 2001; 33: 561-573.
13. Hohimer AR et al. Repeated daily injections and osmotic pump infusion of isoproterenol cause similar increases in cardiac mass but have different effects on blood pressure. Can J Physiol Pharmacol 2005; 83: 191-197.
14. Kuzman JA et al. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy. Endocrinology 2007; 148: 3477-3484.
15. Schlaich MP et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108: 560-565.
16. Burns J et al. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation 2007; 115: 1999-2005.
17. Dúbrava J, Cagán S. Neurohumoral activation and remodeling after acute myocardial infarct and the effect of angiotensinconverting enzyme inhibitors. Bratisl Lek Listy 1993; 94: 88-93.
18. Remme WJ. Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy. Cardiovasc Drugs Ther 2003; 17: 349-360.
19. Esler M et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988; 11: 3-20.
20. Szabó J et al. Experimental cardiac hypertrophy induced by isoproterenol in the rat. Acta Physiol Acad Sci Hung 1975; 46: 281-285.
21. Taylor PB, Tang Q. Development of isoproterenol-induced cardiac hypertrophy. Can J Physiol Pharmacol 1984; 62: 384-389.
22. Tang Q et al. Catecholamine induced cardiac hypertrophy. Can J Cardiol 1987; 3: 311-316.
23. Golomb E et al. Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. Am J Physiol 1994; 267: H1496-H1506.
24. Ocaranza MP et al. Isoproterenol and angiotensin I-converting enzyme in lung, left ventricle, and plasma during myocardial hypertrophy and fibrosis. J Cardiovasc Pharmacol 2002; 40: 246-254.
25. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12: 205S-213S.
26. Adams KF, Jr. Pathophysiologic role of the renin-angiotensinaldosterone and sympathetic nervous systems in heart failure.Am J Health-Syst Pharm 2004; 61: S4-S13.
27. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeing and inflammation: a clinical review. J Hypertens 2006; 24: 983-991.
28. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005; 26: 704-728.
29. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116: 1725-1735.
30. Karsanov NV et al. Regulation of RNA synthesis in the rat heart in L-thyroxine toxicosis and hypothyroidism; the role of RNApolymerases and the template activity of chromatin. Ukr Biokhim Zh 1986; 58: 8-15.
31. Hu LW et al. Myocardial ultrastructure in cardiac hypertrophy induced by thyroid hormone - an acute study in rats. Virchows Arch 2005; 446: 265-269.
32. Sanford CF et al. Synthesis and degradation of myocardial protein during the development and regression of thyroxineinduced cardiac hypertrophy in rats. Circ Res 1978; 43: 688-694.
33. Fernandes ML et al. Spironolactone effects on myocardium changes induced by thyroid hormone in rats. Arq Bras Cardiol 2007; 89: 398-402.
34. Heide SM et al. Metabolism of thyroid hormones in cultured cardiac fibroblasts of neonatal rats. J Endocrinol 2002; 174: 111-119.
35. Brown RD et al. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005; 45: 657-687.
36. Slǎtineanu L et al. Correlation between plasma level of endothelin-1 and heart remodeling in dilated cardiomyopathy. Rev Med Chir Soc Med Nat Iasi 2007; 111: 345-351.
37. Kinugawa T et al. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. J Card Fail 2003; 9: 318-324.